ER POSITIVE BREAST CANCER
Clinical trials for ER POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis phase 2 trial is testing whether giving a combination of three drugs—neratinib, an aromatase inhibitor (letrozole or anastrozole), and trastuzumab—before surgery can completely eliminate invasive breast cancer in postmenopausal women with ER-positive, HER2-positive breast ca…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Ruth O'Regan • Aim: Disease control
Last updated Jun 23, 2026 23:35 UTC
-
Blood test catches cancer early: new drug aims to stop spread
Disease control Recruiting nowThis Phase 3 trial tests whether elacestrant, a new hormone therapy, can prevent distant metastasis better than standard hormone therapies in 220 patients with ER+/HER2- breast cancer whose blood tests show signs of cancer DNA (ctDNA) but no visible spread. Participants are rando…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 23, 2026 12:01 UTC
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial is testing a new drug called palazestrant (OP-1250) combined with ribociclib against the standard letrozole plus ribociclib for people with ER+, HER2- advanced breast cancer who haven't had prior treatment. About 1,000 participants will be randomly assigned to …
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 22, 2026 11:59 UTC
-
New hope for breast cancer patients when first treatment fails
Disease control Recruiting nowThis study tests a combination of two drugs, fulvestrant and abemaciclib, for people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a first-line treatment called a CDK4/6 inhibitor. The goal is to see if taking a break fr…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New hope for advanced breast cancer: drug combo trial opens
Disease control Recruiting nowThis early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC
-
New hope for advanced breast cancer: OP-1250 faces off against standard care
Disease control Recruiting nowThis study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
Promising combo aims to stall advanced breast cancer
Disease control Recruiting nowThis study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2- with an ESR1 mutation) live longer without their cancer getting worse. About 240 adults whose cancer has stopped responding to standard hormone thera…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC